BioSpace News Archive

Data published in The Journal of Diabetes Science and Technology (JDST) demonstrate clinically significant drop in Hemoglobin A1c (HbA1c) for participants in Onduo’s virtual diabetes clinic, especially those with highest need (HbA1c > 9%).

Rezolute, Inc.(“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase Conference in San Francisco on Monday, January 13, 2020 at 9:00 a.m. PT.

Also published was a peer-reviewed research article in the prestigious oncology journal Cancers.

Stratify Genomics, a pioneer in genetic cancer risk tests for the general population, today announced that its Prompt PGS test for lifetime risk of developing prostate cancer has been validated on Hispanic male patients.

Mindray, a global leader in the development of innovative healthcare technology, today announced the launch of its newest ultrasound machine: The DC-90 with X-Insight.

Alcyone Lifesciences, Inc., a biotechnology company dedicated to precision administered genetic therapies to treat complex neurological and oncological conditions through the company’s proprietary advanced precision delivery platforms, looks forward to attending the 9th Annual CureSMA Gala “Hope on the Hill” Congressional Dinner, Tuesday, December 3, 2019 on Capitol Hill in Washington D.C.

As part of Canon Inc.’s global medical business strategic realignment, the X-ray business operations within Canon U.S.A. Inc.’s wholly owned subsidiary Virtual Imaging, Inc. will transfer to Canon Medical Systems USA, Inc. (CMSU) effective January 1, 202

Physicians can now scan faster while maintaining MR image resolution with Compressed SPEEDER technology (pending 510(k) clearance) from Canon Medical Systems USA, Inc.

Athletico Physical Therapy has opened a new location in Sylvania on Monday, November 25th and is conveniently located in the Promenade Shoppes, Across from Vin Dever Autohaus next to Koto Buki and 5th Street Pub.

Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Rivastigmine Transdermal System in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours strengths (generic for Exelon® Patch by Novartis).